Navigation Links
Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter
Date:9/3/2008

BRUSSELS, Belgium and GENEVA, Sept. 3 /PRNewswire/ -- Artelis SA and Selexis SA announced today a new milestone in CHO based monoclonal antibody production with the achievement of manufacturing yields of over 31 grams per liter. This record level was accomplished by applying two highly innovative technologies: (1) a high-performance stable Selexis CHO production cell line rapidly generated by industry leading scientists at Selexis SA using their proprietary Selexis Genetic Elements(TM) and (2) the application of iCELLis(TM) scalable, disposable, high-cell-density technology developed by the innovative scientists at Artelis.

The full program was concluded over about 4 months, starting with the development of a high-performance cell line development at Selexis, followed by cell transfer and manufacturing at Artelis. The culture media used throughout the study was industry standard cGMP grade and void of serum or any animal derived components.

Dr. Igor Fisch, Co-founder and CEO of Selexis commented on the achievements:

"The productivity and stability of the Selexis high-performance cell lines are a perfect fit for the iCELLis(TM) technology, which has the ability to reach incredibly high-cell-densities of up to 250 mio cells per ml". "The usefulness and potential applications of the combined approach could stretch across the biotech industry, beyond just large scale bioproduction".

Dr. Jose Castillo, Co-founder and President of Artelis commented on the achievements:

"These results show the power of the iCELLis(TM) technology. When combined with a high-performance cell line, like one from Selexis', we have the opportunity to reach ultra high productivity levels." "We firmly believe the iCELLis(TM) system will change the approach companies take for the small and large scale production of recombinant proteins."

Further details on this milestone achievement will be presented at the upcoming Bioprocess International Conferenc
'/>"/>

SOURCE Selexis
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
2. Previous Claims of siRNA Therapeutic Effects Called into Question by Report in Human Gene Therapy
3. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
4. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
5. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
6. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
7. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
8. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
9. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
10. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. New AVAC Report on Pre-Exposure Prophylaxis Calls for Immediate Planning to Anticipate Study Results of Potential New HIV Prevention Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 NeuroDerm, ... study in volunteers, and preliminary results from a phase ... presented at the 2013 International Congress of Parkinson,s Disease ... drug formula under development for continuous administration through a ... plasma concentrations. ND0612 has been shown in ...
(Date:6/19/2013)... N.J. , June 19, 2013 /PRNewswire-iReach/ ... Pharma, a new specialty pharmaceutical company dedicated ... of innovative injectable and sustained release drug ... unmet medical needs, today announced the acquisition ... Linker Technology®) platform and associated product pipeline. ...
(Date:6/19/2013)... Calif. , June 19, 2013 ... management solutions, introduced the next-generation of its ... which allows health plans to provide their employer ... populations, health factors, medical and prescription drug claims, ... (Logo: http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) ...
Breaking Medicine Technology:NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 3Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 4MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2
... May 11, 2011 Reportlinker.com announces ... is available in its catalogue: ... 2011 – Generics Market Overview: Patent ... uptake despite tougher market conditions ...
... Daiichi Sankyo announced that applications have been submitted ... of metastatic melanoma to the U.S. Food and Drug ... a pre-marketing application for approval for a companion diagnostic ... also will be registered in Europe.  Vemurafenib is an ...
Cached Medicine Technology:Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions 2Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions 3Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions 4Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions 5Vemurafenib New Drug Application Submitted to FDA for Melanoma 2Vemurafenib New Drug Application Submitted to FDA for Melanoma 3Vemurafenib New Drug Application Submitted to FDA for Melanoma 4
(Date:6/19/2013)... 19, 2013 Maui'd Forever , ... to being an effective and cost effective way to ... have partnered up with Tom Barefoot’s Tours providing an ... most of Hawaii’s activities. , They have just released ... get the lowest prices on their Hawaii activities. ...
(Date:6/19/2013)... 2013 According to Transparency Market Research ... Trends, Analysis and Forecast, 2011 – 2017,” the global ... the year 2011 and is expected to reach USD ... 9.7% from 2011 to 2017. Flexible endoscopes formed the ... USD 2,201 million for the year 2011. , Related ...
(Date:6/19/2013)... treating stroke victims has been "time equals brain." That,s because ... a drug that dissolves the stroke-causing blood clot can make ... or lost. , But specific information has been ... drug known as a tissue plasminogen activator, or tPA ... most common type of stroke. , Now, a ...
(Date:6/19/2013)... MAYWOOD, Il. A Loyola University Chicago Niehoff School ... grant to study whether Vitamin D can improve mood ... study also will examine whether vitamin D supplementation can ... their diabetes. The grant is from the National Institute ... , Principal investigator Sue M. Penckofer, PhD, RN and ...
(Date:6/19/2013)... AquaPrint Solutions in Thomson, IL is proud to ... newly-designed Harley Davidson motorcycle gas tank. A couple of weeks ... idea of taking a split tank motorcycle that had been ... into a work of art. , In October of ... seats that had been dipped in a water transfer printer ...
Breaking Medicine News(10 mins):Health News:Maui'd Forever Pleased to Offer Price Guarantee on Hawaii Activities 2Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 2Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 3Health News:Timely treatment after stroke is crucial, UCLA researchers report 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 3Health News:Loyola receives $1.5 million grant to study vitamin D for diabetes and depression 2Health News:AquaPrint Solutions Transforms Harley Davidson Gas Tank into a Work Of Art for Poopy’s Pub & Grub 2
... IL, April 7, 2009) Managing pain in the ICU ... team. However, new reports suggest that taking a comprehensive approach ... in the ICU and even decreasing the incidence of preventable ... CHEST , the peer-reviewed journal of the American College of ...
... for Usability Evaluation of HIT ProvidersCHICAGO, April 7 ... usability of Electronic Health Records (EHRs), User Centric ( ... performance research designed to provide end-users with real data ... the key limiting factors to adoption now is usability. ...
... designed to benefit individuals with autism and their ... America (ASA), the leading grassroots autism organization and ... medical information services, have teamed up to provide ... the spectrum and their families through the MedicAlert(R) ...
... Mass., April 7 Gene Network Sciences, Inc. today ... researcher in the field of genomics-driven drug discovery, co-chair ... be leaving his position as Executive Scientific ... forces with the departing head of Merck oncology, Dr. ...
... with the autoimmune disease systemic lupus erythematosus (SLE) is ... Hormones secreted by the body are therefore believed to ... disease. A new large, population-based observational study found that ... increased risk of SLE, particularly among women who had ...
... Coverage for RetireesJACKSONVILLE, Fla. , April 7 ... health care coverage to retirees, Blue Cross and ... Group Supplement insurance plans. BlueMedicare Group Supplement is ... who are 65 and older.(Logo: ...
Cached Medicine News:Health News:'Pain in the ICU' report suggests comprehensive approach 2Health News:'Pain in the ICU' report suggests comprehensive approach 3Health News:EMRs Put to the Test on Usability 2Health News:EMRs Put to the Test on Usability 3Health News:Autism Society of America Joins MedicAlert Foundation to offer MedicAlert(R) + Safe and Sound(R) - 24-Hour Comprehensive Protection System 2Health News:Gene Network Sciences Names Departing Merck Head of Genetics Eric Schadt as Co-Chair of Scientific Advisory Board 2Health News:Gene Network Sciences Names Departing Merck Head of Genetics Eric Schadt as Co-Chair of Scientific Advisory Board 3Health News:Oral contraceptives associated with increased risk of lupus 2Health News:Blue Cross and Blue Shield of Florida Introduces BlueMedicare(SM) Group Supplement 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: